Form 4: Vera Therapeutics CFO Sells Shares for Tax Obligations

Vera Therapeutics' Chief Financial Officer, Sean Grant, sold 4,949 shares of Class A Common Stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Sean Grant, Chief Financial Officer of Vera Therapeutics, Inc., sold 4,949 shares of Class A Common Stock.
• The sale occurred over two business days, beginning on February 23, 2026, and ending on February 24, 2026, at a weighted-average price of $41.9839 per share.
• This transaction was a non-discretionary "sell-to-cover" sale, mandated by the Issuer's equity incentive plans to satisfy tax withholding obligations incurred upon the vesting of restricted stock units.
• Following the transaction, Mr. Grant directly beneficially owns 114,181 shares and indirectly owns 5,000 shares through a trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it is a non-discretionary, mandated 'sell-to-cover' transaction for tax purposes, which is a routine part of executive compensation.

Positives

• The transaction was a non-discretionary sale solely to cover tax withholding obligations, indicating it is not a reflection of a change in the CFO's personal investment sentiment towards the company.

Negatives

• The sale reduces the CFO's direct beneficial ownership by 4,949 shares.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it pertains solely to an insider transaction.

Management Comments

• The sale was mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the reporting person.

Industry Context

StockSavvy.ai notes that 'sell-to-cover' transactions for tax withholding upon RSU vesting are a common and routine occurrence for executives in publicly traded companies across all industries. This specific transaction does not reflect broader industry trends or competitive positioning.

Comparison to Industry Standards

• StockSavvy.ai finds that 'sell-to-cover' transactions are standard practice for managing tax liabilities associated with equity compensation across various industries. There are no specific comparable companies or projects relevant to this routine insider transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact, as it's a routine, non-discretionary sale for tax purposes by an executive. The reduction in direct ownership is small relative to total shares outstanding.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The Reporting Person will provide full information regarding the number of shares sold at each separate price upon request to the SEC staff, the Issuer, or any security holder.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary 'sell-to-cover' transaction by the CFO to satisfy tax obligations from RSU vesting. It does not indicate any change in the company's fundamentals, strategic direction, or the CFO's personal investment conviction. Therefore, it provides no new information that would warrant a change in an investor's current position, suggesting a 'hold' recommendation.

Keywords

Vera Therapeutics, VERA, Form 4, Insider Transaction, Sean Grant, CFO, Restricted Stock Units, RSU, Sell-to-Cover, Tax Withholding